Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 901–1,000 of 2,053
Bhattacharya, S., & Kalra, S. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.2.1 · Cited by 3
“In most Western guidelines, sulphonylureas are a third or fourth option glucoselowering drug as they cause hypoglycaemia and weight gain, and their cardiovascular safety is equivocal.(1,12) However, they continue to be a popular choice in developing countries.”
BackgroundSURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Frandsen, C. S., & Madsbad, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01292-8 · Cited by 3
Ishii, H., Kamei, N., Shimono, D., Niiya, T., Tosaki, T., Kitazawa, T., Suzuki, D., Wakasa, Y., Seino, H., Oishi, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01442-0 · Cited by 2
Pandolfo, I. L., Bonifácio, M., Benfato, I. D., Cruz, M. D. A., Nagaoka, M. R., Carvalho, C. P. D. F., de Oliveira, C. A. M., & Rennó, A. C. M. (2023) · Journal of Biophotonics · doi:10.1002/jbio.202300182 · Cited by 3
A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
Gkrinia, E. M. M., Faour, A. K., Belančić, A., Bazile, J., Marland, E., & Vitezić, D. (2023) · Diabetology · doi:10.3390/diabetology4040038 · Cited by 3
“…53 mmol/mol (7%), which is the average blood glucose level over 3 months, results in the substantial reduction in the onset and progression of macrovascular (e.g., coronary heart disease, cerebrovascular disease) and microvascular (e.g., diabetic nephropathy, retinopathy) complications [5–9].”
BackgroundInfluentialDiallo, A., Villard, O., Carlos‐Bolumbu, M., Renard, É., & Galtier, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15335 · Cited by 4
“6,7 From this point of view, it is particularly interesting to consider both glycae-mic control and weight, as these two variables do not necessarily vary in the same direction and depend not only on dietary management but also on the specific effects of the treatments used.”
BackgroundPark, S., Jeong, J., Woo, Y., Choi, Y. J., & Shin, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-45793-x · Cited by 4
Rodrigues, M. F. G., Araújo, A. H. M., Oliveira, F. C. M., Leal, I. B. F., Andrade, I. F. D., & de Sousa, M. N. A. (2023) · Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · doi:10.36692/v15n3-56r · Cited by 6
Hábitos Alimentares das Pessoas com Diabetes Mellitus Tipo 2 em Portugal: Um Estudo Transversal
Rodriguez, B., Rosendo, I., Coelho, T., Mendes, P. D., Rodrigues, G. D. S., Francisco, Â. F., Martins, A. S. C., Boto, T., Fernandes, F. G., Costa, Â. F., et al. (2024) · Acta Médica Portuguesa · doi:10.20344/amp.19738 · Cited by 6
Wijma, A. G., Driessens, H., Nijkamp, M. W., Hoogwater, F. J. H., van Dijk, P. R., & Klaase, J. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002300 · Cited by 8
Primary Care and Diabetes Technologies and Treatments
Martens, T. W., Simonson, G. D., Carlson, A. L., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2510 · Cited by 3
“Finally,2022–2023 saw the publication of consensus guidelines by the American Diabetes Association and European Association for the Study of Diabetes regarding management of hyperglycemia in T2D, consolidating the consensus around the use of glucagon-like peptide receptor 1 (GLP-1R) agonist and sodium glucose cotransp…”
InfluentialMitsuboshi, S., Morizumi, M., Kotake, K., Kaseda, R., & Narita, I. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14014 · Cited by 4
Delevatti, R. S., Leonel, L. D. S., & Wolin, I. A. V. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111379 · Cited by 5
Tyebkhan, G., Velaskar, S., Yadav, P., Phiske, M. M., & Shah, D. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0569 · Cited by 8
Kis, J. T., Seufert, J., Haluzík, M., Bonnemaire, M., Vera, C., Tournay, M., Freemantle, N., & Guja, C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01644-0 · Cited by 4
“Considering the heterogeneity of T2D, the latest consensus report from the ADA and the European Association for the Study of Diabetes (EASD) emphasizes personalizing treatment strategies to incorporate individual-specific factors while selecting the appropriate glucose-lowering treatment [12].”
Wei, J., Wu, H., Zheng, Y., Wang, N., Benedict, C., Chen, W., & Tan, X. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111927 · Cited by 3
“In addition to the medication, treatment regimen of T2D should also involve lifestyle modifications, such as healthy diet and physical activity [3].”
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-1160 · Cited by 3
Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
Cosentino, F., Dagogo-Jack, S. E., Frederich, R. C., Cannon, C. P., Cherney, D. Z. I., Mancuso, J. P., Wynant, W., Xing, A., Gantz, I., Cater, N. B., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16050 · Cited by 4
Pazzagli, L., Odsbu, I., Cesta, C. E., Bellocco, R., Lagerros, Y. T., & Pasternak, B. (2025) · Clinical and Translational Science · doi:10.1111/cts.70174 · Cited by 4
Vilsbøll, T., Fu, A., Kellerer, M., Kumar, B., Søgaard, S. B., & Goldenberg, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16328 · Cited by 6
Zhang, L., Kulkarni, P., Farshidfar, F., Tingley, W. G., Hoey, T., Wang, W., Priest, J. R., & Figarska, S. M. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04753-1 · Cited by 3
“Cardiovascular safety has been a concern for antidiabetic treatment for years [39, 40] and therefore in this study we investigated longitudinal effects of genetic proxies or sulfonylureas and GLP1R agonists.”
Liu, Q., Ren, B., Yin, L., Lin, S., Lei, S., Liu, W., Zhu, X., & Feng, B. (2025) · BMC Public Health · doi:10.1186/s12889-025-24717-6 · Cited by 6
“…interventions for T2DM is patient-centered self-management measures combined with expert-led treatment programs to improve patient knowledge, attitude, and behavior (KAB) as well as medication taking, reduce glycated hemoglobin (A1C) levels, and decrease the incidence of complications [7, 8].”
Chemical Constituents of Artemisia Annua are Potent Inhibitors of Alpha-Amylase in Type II Diabetes
Dilshad, E., Mehmood, F., Tariq, R., Munir, A., & Fazal, S. (2021) · Life and Science · doi:10.37185/lns.1.1.194 · Cited by 3
Metformin – régi motoros erősebb motorral
Winkler, G. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.24 · Cited by 2
Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 5
“Providers must simultaneously consider glucose-lowering ability, costs, side-effect profiles, contraindications and cardiorenal risk factors, as well as any non-glycaemic benefits of specific agents [13, 36].”
BackgroundMethodInfluentialVACCINES VERSUS COVID-19 VACCINES: MANEUVER TIMELINE OF DEVELOPMENT AND TRIAL DESIGNS
Gaddam, S., Pasupulati, H., & Padi, S. S. V. (2023) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v5i3.265 · Cited by 6
“complete remission, such as tamoxifen in breast cancer and fluoxetine in major depression or used for whole life in chronic or life-term diseases, such as metformin in type 2 diabetes mellitus and statins in hyperlipidemia [26,30,31].”
BackgroundDietary Modulation of Chronic Inflammation of Diabetes: A Narrative Review
Joseph, S. (2023) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000181 · Cited by 2
Perreault, L., & Bergman, B. C. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13505 · Cited by 3
Yuniarto, A., Junaidin, Setiawan, A. A., Juanda, D., Ardiansyah, A., & Saraswaty, V. (2025) · Talanta Open · doi:10.1016/j.talo.2025.100569 · Cited by 9
Zabala, A., Gottsäter, A., Lind, M., Eliasson, B., Bertilsson, R., Ekelund, J., Jonsson, M., & Nyström, T. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231176767 · Cited by 4
“In people undergoing vascular surgery, a relationship between preoperative glycemic control, measured by HbA1c, and risk for long-term complication has been demonstrated.(26,25,30,31) Today no Figure 2.”
BackgroundKleinjan, J. P., Blom, J., van Beek, A. P., Bouma, H. R., & van Dijk, P. R. (2024) · Metabolites · doi:10.3390/metabo14030162 · Cited by 5
“Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are effective drugs in the management of type 2 diabetes as they improve glycaemic control, promote weight loss, and mitigate cardiovascular risk and the progression of chronic kidney disease [1].”
BackgroundWound bed preparation 2024: Delphi consensus on foot ulcer management in resource-limited settings
Smart, H. (2024) · WCET Journal · doi:10.33235/wcet.44.1.13-35 · Cited by 2
Oe, M., Fujihara, K., Yamada, M. H., OSAWA, T., Kitazawa, M., Matsubayashi, Y., Sato, T., Yaguchi, Y., Iwanaga, M., Yamada, T., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14277 · Cited by 3
The effect of the keto diet on lipid profile with type two diabetic patients
Ghassan, F., Mohammed, A., & Kazim, Z. (2024) · Drug development & registration · doi:10.33380/2305-2066-2024-13-4-1820 · Cited by 3
Aranishi, T., Igarashi, A., Hara, K., Osumili, B., Cai, Z., Mizogaki, A., Sato, M., Takeuchi, M., Minghetti, A., Hunt, B., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01675-7 · Cited by 2
“The disease is associated with an increased risk of macro-and microvascular complications which, in turn, lead to large health and economic burdens [2].”
Dunn, T. J., Cao, Y., Xie, L. Y., Guevarra, M., & Mitri, J. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.24251 · Cited by 2
Nguyen, T. T., & Elmaleh, D. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030812 · Cited by 3
“Weight loss in the range of 10–15% and greater has resulted in, specifically, the remission of T2D (not fully cured), improvement in patients with heart failure, and reduced cardiovascular mortality [22,23].”
Campbell, K., Ashton, N., Peddie, M. C., Ma’ia’i, K., Camp, J., Mann, J., & Reynolds, A. N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16240 · Cited by 2
Buraczyńska, M., Boczkowska, S., & Załuska, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s506639 · Cited by 5
Cao, M., Lin, Q., Lin, L., Zhang, W., & Zhang, L. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-54743 · Cited by 2
“…reflect the status of acute myocardial injury and thrombosis, while the mechanism of action of empagliflozin is more about improving glucose and lipid metabolism and cardiac and renal function, with its direct impact on acute myocardial injury or thrombosis being relatively minor (12, 31, 32).”
Pop, C., Petriş, A. O., Pop, L., & David, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103269 · Cited by 10
“Current guidelines recommend the early use of SGLT2 inhibitors in T2DM treatment, particularly for patients with established or high risk of atherosclerotic cardio-vascular disease (ASCVD), HF, or CKD [46–48].”
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., Fatima, B., & Abughosh, S. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109080 · Cited by 2
Birgisdóttir, M., Skúladóttir, H., & Sigurðardóttir, Á. K. (2025) · International Journal of Circumpolar Health · doi:10.1080/22423982.2025.2517932 · Cited by 2
“Appropriate self-management includes good metabolic control and addressing risk factors related to T2D co-morbidities, such as cardiovascular complications [2].”
InfluentialAbu-Alsaud, M. A., Ellebedy, M., Hammad, N., Lamie, M. I., & El-Rawy, A. F. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_213_24 · Cited by 2
Peripheral artery disease In West Africans with diabetes: a risk factor profile analysis
Amoako, J. K. A., Saa, M. F., Bannerman-Williams, E., Bruce, A. N. K., Ansong, M. B., Danquah, A., Ablorh, A., Kwaw, W. N. A., Adjei, M., Awuttey, E. K., et al. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200469 · Cited by 4
“Optimum glycemic control was defined as an HbA 1 c concentration of ≤ 7 %, based on the American Diabetes Association and European Association for the Study of Diabetes consensus algorithm; this cut-off value is associated with benefits, including reducing vascular complications [26,27].”
The impact of epigenetic factors in type 2 diabetes: Insights into development and pathogenesis
Thammanna Gowda, S. S., Rangappa, S., & Hanumesh, P. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100635 · Cited by 3
Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada
Garcia, D., Mau, G., Singh, S. R., Spence, M., Jensen, M. S., & Goldenberg, R. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2551449 · Cited by 4
“Uncontrolled diabetes is associated with considerable morbidity and mortality, including an increased risk of developing microvascular (i.e. retinopathy, nephropathy, and neuropathy) and macrovascular (i.e. stroke, heart failure, myocardial infarction, and other cardiovascular events) complications 5 , which significa…”
InfluentialFan, Y., Wu, L., Zhang, Y., Hu, Q., Mei, J., Prabahar, K., Hernández‐Wolters, B., Kord‐Varkaneh, H., Lei, C., & Zheng, S. J. (2025) · Phytotherapy Research · doi:10.1002/ptr.70071 · Cited by 2
“Despite the availability of various medications for managing type 2 diabetes, the prevalence of diabetes-related complications and mortality continues to rise (Davies et al. 2022).”
Kushner, P. R., Campos, C., King, A., Kruger, D. F., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0037 · Cited by 3
Nikolaidis, S., Kosmidis, I., Papadopoulos, S., Lioupi, A., Gandanidou, M., Gika, H., Dokoumetzidis, A., Theodoridis, G. A., & Mougios, V. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70208 · Cited by 2
“Metformin is recommended as monotherapy for prediabetes (Elsayed et al., 2024) and is the first-line agent approved for T2D (ADA, 2020; Davies et al., 2022).”
Gutowska, K., Ambroziak, M., Podraza, J., Puzianowska‐Kuźnicka, M., Czajkowski, K., Budaj, A., & Kuryłowicz, A. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02215-3 · Cited by 2
“…was assessed by history and treatment or by a fasting plasma glucose level ≥ 126 mg/dl (7.0 mmol/l) or ≥ 200 mg/dl (11.1 mmol/l) in an oral glucose tolerance test or an HbA1c value ≥ 6.5% according to the European Association for Study of Diabetes and American Diabetes Association guidelines [25].”
InfluentialUnderstanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.10.001 · Cited by 2
Diaz, M. M., Herrera‐Pérez, E., Montesinos, R., Tiwari, C., Custodio, N., & Lanata, S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70798 · Cited by 2
“18 We collected data on their native language, defined as the first language that the participant learned to speak, but all participants spoke fluent Spanish.”
Alam, A. B. M. N., Gill, N., Han, I., Nagasaka, R., Hu, W., & SHAMSUDDIN, L. S. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.10.001 · Cited by 3
Buse, J. B., Christensen, H. N., Harty, B. J., Cziraky, M. J., Willey, V. J., & Skibsted, S. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005161 · Cited by 6
Self-citationAbdelhafiz, A. H., Siqueira, I., & Sinclair, A. J. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109193 · Cited by 5
Rädel, C., Wienke, A., & Pliquett, R. U. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01976-2 · Cited by 2
“According to International Guidelines [4, 5], type-2-diabetes therapy is being allocated in a stepwise manner, but in an individualized way.”
Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes
Sneed, N. M., Rifas‐Shiman, S. L., Petimar, J., Young, J. G., Bailey, L. C., Daley, M. F., Janicke, D. M., Jones, W. S., Prentice, C., Block, J. P., et al. (2025) · Obesity · doi:10.1002/oby.70022 · Cited by 2
Sanyal, D., Saboo, B., Phatak, S., Kumar, P. K. M., Basu, D., Verma, N., NAIR, A., Bhattacharjee, K., Aneja, P., Makkar, B. M., et al. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_179_25 · Cited by 3
“%) participants experienced a total of 96 AEs [Table 2].”
Menzella, F., Cottini, M., & Chan, R. (2025) · Journal of International Medical Research · doi:10.1177/03000605251392717 · Cited by 5
“23 Although bariatric surgery can lead to substantial and sustained improvements in asthma con-trol, exacerbation rates, and medication requirements, it is an invasive procedure reserved for selected candidates and is not suitable or accessible for all patients.”
Seo, D. H., Min, K. W., Sohn, H. S., Kim, S. Y., Jeong, I., Park, C., Yoon, K., Kim, S. H., & Cha, B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70257 · Cited by 4
Piccione, A., Bonsangue, M., Barone, M., Vigneri, E., Mineo, M. I., Tomasello, L., Maniscalco, L., Pantò, F., Arnaldi, G., & Guarnotta, V. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104462 · Cited by 2
Shahidifar, E., Lesniowska, M., Deschenes, E., POLCHA, G., Manzo, C. E., Barreiro, T. J., Bigdeli, G., Hemmat, A., Brine, P., Malik, A. K., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09570-2 · Cited by 6
Zhou, S., Zhang, K., Cai, B., Li, J., & Yin, G. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00430-7 · Cited by 2
“In 2022, the American Diabetes Association and the European Association for the Study of Diabetes jointly published the “Consensus Report on Pharmacological Treatment of Type 2 Diabetes,” which still lists it as a first-line hypoglyce - mic agent [1].”
Brown, J. V. E., Carswell, C., Podmore, D., Featherstone, I., Alderson, S. L., Böhnke, J. R., Doran, T., Hadjiconstantinou, M., Hewitt, C. E., Holt, R. I. G., et al. (2025) · Frontiers in Health Services · doi:10.3389/frhs.2025.1688787 · Cited by 3
ElBadawi, H., Albalkhi, N., Kadhim, I. A., Elsadig, A. E., Baltzis, D., Hatahet, M. H., Ismail, M., Khader, S., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70317 · Cited by 2
Jain, A., Kristensen, P. N., Wasehuus, R. S., Kruse, C., & Nørtoft, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70350 · Cited by 3
“…and T2D is associated with improved glycaemic control and reduced progression of T2D, 9 and international guidelines (American Diabetes Association [ADA] 2025 10 ; ADA/European Association for the Study of Diabetes [EASD] 2022 11 ) recognize weight management as a primary treatment goal for T2D.”
Novodvorský, P., Thieme, L., Laňková, I., Franková, Š., Veselá, A., Záhumenský, E., Edelsberger, T., Löblová, M., Žižka, O., Vytasil, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70362 · Cited by 5
Ali, M., Amirthalingam, P., Alshareef, H., Alqifari, S., Elsaid Hamdan, A., Alatawi, O., Hakami, F., Albalawi, N., & Aljabri, A. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s569096 · Cited by 2
“37”
Yu, D., Zou, M., cheng, B., Yang, P., Huang, D., Pan, Q., & Guo, L. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.11.025 · Cited by 2
Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients
Roth, L., Stein, J., & Schwarz, P. E. H. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6671361 · Cited by 2
Bogaert, L., Craemer, M. D., Dirinck, E. L., Calders, P., Lapauw, B., & Willems, I. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-098988 · Cited by 3
Urea cycle modulation by combined SGLT2 inhibitors and metformin
Harada, M., Adam, J., Han, S., Shi, M., Ge, J., Lintelmann, J., Cecil, A., Zukunft, S., Prehn, C. P., Witting, M. A., et al. (2026) · BMC Medicine · doi:10.1186/s12916-025-04609-7 · Cited by 3
“Clinical guidelines recommend metformin as the first-line therapy for T2D, with sodium-glucose co-transporter 2 inhibitors (SGLT2i) as an add-on therapy for patients at high risk of cardiovascular and renal complications [2, 4].”
Kamrul-Hasan, A. B. M., Chatterjee, S., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf238 · Cited by 5
Prisacariu, I., Iorescu, L.-V., aboueddahab, C., Taheri, M., Beneki, E., Akıncı, B., Baťalík, L., Dumitrescu, S. I., Marketou, M. E., & Perone, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031103 · Cited by 5
“%) may be appropriate in elderly or frail patients [54].”
Campana, C., Heaney, A., Ceraolo, N., Srinivas, S., & Simon, E. L. (2026) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2026.01.002 · Cited by 3
Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications
Matera, M. G., Page, C. P., Calzetta, L., Rogliani, P., & Cazzola, M. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2632668 · Cited by 3
“Therefore, management of patients with comorbid asthma and T2DM requires careful therapeutic consideration, and both the ADA and the European Association for the Study of Diabetes recommend a person-centered approach integrating comorbidities into treatment planning [75].”
InfluentialBiddle, S., Brierley, M. L., Castle, E. M., Hunt, E. R., Chater, A., Edwardson, C. L., & Bailey, D. P. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-101309 · Cited by 3
“( RS14, IG) For some, participants altered typical sedentary tasks to reduce sitting, such as when working on computers and speaking on the telephone: When I’m working on computer, as I work for [charity name] as well.”
Xie, L., Shu, T., Yuan, Z., Jiang, M., Liu, D., Yang, W., & Xie, H. (2026) · Health Education Research · doi:10.1093/her/cyag005 · Cited by 2
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
Guo, M., Chen, S., Dong, H., Cai, M., Guo, M., & Cheng, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05113-2 · Cited by 2
“…sarcopenia, tendon disorders, and connective tissue abnormalities, which may substantially impair physical function and quality of life and contribute to frailty and disability (Chen et al. 2023), (Courties and Sellam 2016), (Davies et al. 2022), (Aoy-ama et al. 2014), (Eitner and Wildemann 2021).”
Wu, T.-E., & Chen, H.-S. (2026) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001370 · Cited by 7
LEWIS, G. A., Hughes, D. E., Irving, G. J., Wilding, J. P. H., & Hardy, K. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70312 · Cited by 2
Hua, J., Wang, Q., Liu, Y., Luo, S., Shi, A., Yan, Z., Zhang, J., Gu, W., Zhu, L., Zhang, Y., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03173-5 · Cited by 4
“The ADA and the European Association for the Study of Diabetes recommend SGLT-2i for patients with T2DM who have established CVD or CKD [162].”
Aroda, V. R., Davies, M. J., Maaske, J., Millegård, M., Juan, V. L., Aberle, J., Ciudin, A., McCrimmon, R. J., Eklund, O., Shih, J. L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00802-0 · Cited by 6
Self-citationEtayo-Urtasun, P., de Asteasu, M. L. S., & Izquierdo, M. (2026) · Sports Medicine · doi:10.1007/s40279-026-02469-6 · Cited by 2
“Supervised programs demonstrate superior efficacy compared with unsupervised approaches and should be individualized based on patient preferences, motivational factors, and contextual circumstances [82, 83].”
Raptis, D. A., Chiotis, S., Papamichalis, T., Bekiari, E., Τσάπας, Α., & Karagiannis, T. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01628-3 · Cited by 4
“…- rary era of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, daily basal insulin has increasingly shifted from first-line injectable therapy to a complementary option when GLP-1 RAs are insufficient, con - traindicated, or when patients present with markedly elevated HbA1c levels [ 41 ].”
Mori, T., Herder, C., Cardoso, P., Dennis, J., & Kuß, O. (2026) · Diabetologia · doi:10.1007/s00125-026-06802-6 · Cited by 4
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 4
Self-citationMora, P., Aroda, V. R., Asong, M., Blüher, M., Heftdal, L. D., Carlander, A. F., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01248-1 · Cited by 5
Self-citationSaleem, M., Khan, S., Suchal, Z. A., et al. (2022) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.5.5034 · Cited by 2
Krajnc, M., & Tramšek, N. A. K. (2023) · European journal of medical research · doi:10.1186/s40001-023-01081-y · Cited by 2
Tsoukas, M. A., Woo, V. C., Tobe, S. W., Slee, A. E., Rapattoni, W., Ang, F. G., Seufert, J., Neuen, B. L., Arnott, C. G., Mahaffey, K. W., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15057 · Cited by 2
Kwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
“Beyond multifactorial lifestyle modifications, a suitable individually tailored pharmacotherapy is the key component of successful diabetes management that prevents or postpones its complications and preserves a satisfactory quality of life [2].”
BackgroundInfluentialKulenović, A., & Lagumdzija-Kulenovic, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101267 · Cited by 2
Бойко, А. І. (2023) · Фармацевтичний часопис · doi:10.11603/2312-0967.2023.1.13913 · Cited by 2
Muh Anshar, J., Kurniawan, L. B., Nurahmi, N., Zainuddin, A. A., Umar, H., & Arif, M. (2023) · FITOFARMAKA Jurnal Ilmiah Farmasi · doi:10.33751/jf.v13i1.7752 · Cited by 2
Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15339 · Cited by 2
Renal elasticity and perfusion changes on ultrasonography in an early-stage diabetic rat model
Li, Y., Liu, Z., Wei, R., et al. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-409 · Cited by 2
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00716-4 · Cited by 4
“In Western countries, metformin used to be recommended as a first-line drug in the guidelines of the treatment for T2DM [6], in recent years, the pharmacologic therapy should be guided by person-centered treatment factors, including comorbidities and treatment goals [7, 8].”
BackgroundTreatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.